中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 1
Jan.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(1): 2-6

Functional cure of chronic hepatitis B is not a dream

DOI: 10.12449/JCH250101

  • Department of Microbiology and Center of Infectious Diseases，Peking University Health Science Center，Beijing 100191，China

More Information
  • Corresponding author: ZHUANG Hui， zhuangbmu@126.com （ORCID： 0000-0001-9119-6325）
  • Received Date: 2024-11-16
  • Accepted Date: 2024-11-28
  • Published Date: 2025-01-25
    Abstract
  • Functional cure of chronic hepatitis B （CHB） is defined as HBsAg<0.05 IU/mL and serum HBV DNA<10 IU/mL for at least 24 weeks after discontinuation of antiviral therapy. This requires suppression of HBV replication and reduction of viral antigen production， as well as restoration of immune response to HBV infection. About 30% — 50% of highly selected CHB patients treated with nucleos（t）ide analogues can achieve functional cure after add-on therapy or monotherapy with pegylated interferon-α or a finite course of treatment with nucleos（t）ide analogues among patients with HBsAg<100 IU/mL. At present， clinical trials are being conducted for more than 40 types of novel anti-HBV drugs and immunomodulators. The combination of drugs that inhibit viral replication， reduce antigen burden， and restore immune response to HBV infection may be an ideal strategy to achieve the functional cure of CHB. However， further studies are needed to determine the optimal drug combination， the timing and sequence of medication， and the duration of treatment.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    CHAI N, CHANG HE, NICOLAS E, et al. Properties of subviral particles of hepatitis B virus[J]. J Virol, 2008, 82( 16): 7812- 7817. DOI: 10.1128/JVI.00561-08.
    [2]
    GANEM D, PRINCE AM. Hepatitis B virus infection: Natural history and clinical consequences[J]. N Engl J Med, 2004, 350( 11): 1118- 1129. DOI: 10.1056/NEJMra031087.
    [3]
    REHERMANN B, LAU D, HOOFNAGLE JH, et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection[J]. J Clin Invest, 1996, 97( 7): 1655- 1665. DOI: 10.1172/JCI118592.
    [4]
    BONI C, LACCABUE D, LAMPERTICO P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues[J]. Gastroenterology, 2012, 143( 4): 963- 973. DOI: 10.1053/j.gastro.2012.07.014.
    [5]
    KIM JH, GHOSH A, AYITHAN N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients[J]. Sci Rep, 2020, 10( 1): 1835. DOI: 10.1038/s41598-020-58870-2.
    [6]
    RINKER F, ZIMMER CL, HÖNER ZU SIEDERDISSEN C, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B[J]. J Hepatol, 2018, 69( 3): 584- 593. DOI: 10.1016/j.jhep.2018.05.004.
    [7]
    van BÖMMEL F, BERG T. Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: A treatment concept for patients with HBeAg-negative chronic hepatitis B[J]. Hepatol Commun, 2021, 5( 10): 1632- 1648. DOI: 10.1002/hep4.1708.
    [8]
    LOK ASF. Toward a functional cure for hepatitis B[J]. Gut Liver, 2024, 18( 4): 593- 601. DOI: 10.5009/gnl240023.
    [9]
    GHANY MG, BUTI M, LAMPERTICO P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference[J]. J Hepatol, 2023, 79( 5): 1254- 1269. DOI: 10.1016/j.jhep.2023.06.002.
    [10]
    LI MH, YI W, ZHANG L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy[J]. J Viral Hepat, 2019, 26( Suppl 1): 32- 41. DOI: 10.1111/jvh.13151.
    [11]
    LI MH, SUN FF, BI XY, et al. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients[J]. Virol Sin, 2022, 37( 3): 390- 397. DOI: 10.1016/j.virs.2022.03.001.
    [12]
    YIP TCF, WONG GLH, WONG VWS, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients[J]. J Hepatol, 2018, 68( 1): 63- 72. DOI: 10.1016/j.jhep.2017.09.018.
    [13]
    LOK AS, ZOULIM F, DUSHEIKO G, et al. Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B[J]. Hepatol Commun, 2019, 4( 1): 8- 20. DOI: 10.1002/hep4.1436.
    [14]
    YIP TCF, LOK ASF. How do we determine whether a functional cure for HBV infection has been achieved?[J]. Clin Gastroenterol Hepatol, 2020, 18( 3): 548- 550. DOI: 10.1016/j.cgh.2019.08.033.
    [15]
    XIE C, LIN BL, XIE DY, et al. Peginterferon alpha-2b promoted HBsAg loss in nucleos(t)ide analogue-treated patients: a large-scale real-world study(Everest Project)[J]. J Hepatol, 2026(Revised).
    [16]
    GAO N, GUAN GW, XU GL, et al. Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy[J]. Aliment Pharmacol Ther, 2023, 58( 10): 1086- 1098. DOI: 10.1111/apt.17670.
    [17]
    HIRODE G, CHOI HSJ, CHEN CH, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort(RETRACT-B study)[J]. Gastroenterology, 2022, 162( 3): 757- 771. DOI: 10.1053/j.gastro.2021.11.002.
    [18]
    LIM SG, TEO AE, CHAN ESY, et al. Stopping nucleos(t)ide analogues in chronic hepatitis B using HBsAg thresholds: A meta-analysis and meta-regression[J]. Clin Gastroenterol Hepatol, 2024. DOI: 10.1016/j.cgh.2024.05.040.[ Online ahead of print]
    [19]
    BLOCK PD, LIM JK. Unmet needs in the clinical management of chronic hepatitis B infection[J]. J Formos Med Assoc, 2024. DOI: 10.1016/j.jfma.2024.08.020.[ Online ahead of print]
    [20]
    PETERS MG, YUEN MF, TERRAULT N, et al. Chronic hepatitis B finite treatment: Similar and different concerns with new drug classes[J]. Clin Infect Dis, 2024, 78( 4): 983- 990. DOI: 10.1093/cid/ciad506.
    [21]
    YUEN MF, LIM SG, PLESNIAK R, et al. Efficacy and safety of Bepirovirsen in chronic hepatitis B infection[J]. N Engl J Med, 2022, 387( 21): 1957- 1968. DOI: 10.1056/NEJMoa2210027.
    [22]
    BUTI M, HEO J, TANAKA Y, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B[J]. J Hepatol, 2024. DOI: 10.1016/j.jhep.2024.08.010.[ Online ahead of print]
    [23]
    Study of Bepirovirsen in nucleos(t)ide analogue-treated participants with chronic hepatitis B(B-Well 1)[R/OL].[ 2024-11-16]. http://ClinicalTrials.gov identifier NCT05630807. http://ClinicalTrials.gov identifier NCT05630807
    [24]
    Study of Bepirovirsen in nucleos(t)ide analogue-treated participants with chronic hepatitis B(B-Well 2)[R/OL].[ 2024-11-16]. http://ClinicalTrials.gov identifier NCT05630820. http://ClinicalTrials.gov identifier NCT05630820
    [25]
    HOU JL, XIE Q, ZHANG WH, et al. OS-030 efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study(PIRANGA)[J]. J Hepatol, 2024, 80: S26. DOI: 10.1016/S0168-8278(24)00471-9.
    [26]
    HOU JL, ZHANG WH, XIE Q, et al. Xalnesiran with or without an immunodulator in chronic hepatitis B[J]. N Engl J Med, 2024, 391( 22): 2098- 2109. DOI: 10.1056/NEJMoa2405485.
    [27]
    AGARWAL K, BUTI M, van BÖMMEL F, et al. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2[J]. J Hepatol, 2024, 81( 3): 404- 414. DOI: 10.1016/j.jhep.2024.03.046.
    [28]
    GOPALAKRISHNA H, GHANY MG. Perspective on emerging therapies to achieve functional cure of chronic hepatitis B[J]. Curr Hepatol Rep, 2024, 23( 2): 241- 252. DOI: 10.1007/s11901-024-00652-9.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (411) PDF downloads(135) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return